Basic Information
RNALocate ID: | RLID:01002279 |
RNA Symbol: | hsa-miR-20b-5p |
Localization: | Cytoplasm |
RNA Information
RNA Name: | hsa-miR-20b |
RNA ID: | miRBase:MIMAT0001413 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21363885 |
Tissue/Cell Line: | Neural progenitor cells |
Method: | Microarray|qRT-PCR |
Description: | The miRNAs with nuclear or cytoplasmic dominance are shown in Table 1 (complete data in Supplement 4). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002278 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01002280 | Mitochondrion | Cell line (HEK-293) | 22984580 |
RLID:01002281 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01002282 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01002283 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11002753 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11002754 | Exosome | Ovarian follicular fluid | 22116803 |
RLID:11002755 | Exosome | Breast milk | 22211110 |
RLID:11002756 | Exosome | Brain tissue | 23382797 |
RLID:11002757 | Exosome | Plasma | 23663360 |
RLID:11002758 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11002759 | Microvesicle | Seminal plasma | 23539611 |
RLID:11002760 | Microvesicle | Follicular fluid | 23666971 |
RLID-D:11000138 | Exosome | Seminal fluid | |
RLID-D:11000451 | Microvesicle | Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-20b-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-27920 |
MNDR | hsa-miR-20b-5p | Oral squamous cell carcinoma | MNDR-E-MI-27921 |
MNDR | hsa-miR-20b-5p | Large cell neuroendocrine cancer | MNDR-E-MI-27922 |
MNDR | hsa-miR-20b-5p | Medulloblastoma | MNDR-E-MI-27923 |
MNDR | hsa-miR-20b-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-27924 |
MNDR | hsa-miR-20b-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-27925 |
MNDR | hsa-miR-20b-5p | Lymphoma | MNDR-E-MI-27926 |
MNDR | hsa-miR-20b-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-27927 |
MNDR | hsa-miR-20b-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-27928 |
MNDR | hsa-miR-20b-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-27929 |
MNDR | hsa-miR-20b-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-27930 |
MNDR | hsa-miR-20b-5p | Her2-receptor positive breast cancer | MNDR-E-MI-27931 |
MNDR | hsa-miR-20b-5p | Breast cancer luminal | MNDR-E-MI-27932 |
MNDR | hsa-miR-20b-5p | Dermatomyositis | MNDR-E-MI-27933 |
MNDR | hsa-miR-20b-5p | Prostate cancer | MNDR-E-MI-27934 |
MNDR | hsa-miR-20b-5p | Gastric cancer | MNDR-E-MI-27935 |
MNDR | hsa-miR-20b-5p | Alzheimer disease | MNDR-E-MI-27936 |
MNDR | hsa-miR-20b-5p | Intracranial aneurysm | MNDR-E-MI-27937 |
MNDR | hsa-miR-20b-5p | Bladder cancer | MNDR-E-MI-27938 |
MNDR | hsa-miR-20b-5p | Esophageal carcinoma | MNDR-E-MI-27939 |
MNDR | hsa-miR-20b-5p | Dysautonomia familial | MNDR-E-MI-27940 |
MNDR | hsa-miR-20b-5p | Leukemia | MNDR-E-MI-27941 |
MNDR | hsa-miR-20b-5p | Friedreich ataxia | MNDR-E-MI-27942 |
MNDR | hsa-miR-20b-5p | Cardiovascular disease | MNDR-E-MI-27943 |
MNDR | hsa-miR-20b-5p | Carotid stenosis | MNDR-E-MI-27944 |
MNDR | hsa-miR-20b-5p | Lung cancer | MNDR-E-MI-27945 |
MNDR | hsa-miR-20b-5p | Parkinson disease | MNDR-E-MI-27946 |
MNDR | hsa-miR-20b-5p | Basal-like breast cancer | MNDR-E-MI-27947 |
MNDR | hsa-miR-20b-5p | Thyroid cancer | MNDR-E-MI-27948 |
MNDR | hsa-miR-20b-5p | Pancreatic cancer | MNDR-E-MI-27949 |
MNDR | hsa-miR-20b-5p | Melanoma | MNDR-E-MI-27950 |
MNDR | hsa-miR-20b-5p | Rectum adenocarcinoma | MNDR-E-MI-27951 |
MNDR | hsa-miR-20b-5p | Nephroblastoma | MNDR-E-MI-27952 |
MNDR | hsa-miR-20b-5p | Colon cancer | MNDR-E-MI-27953 |
MNDR | hsa-miR-20b-5p | Ischemic attack transient | MNDR-E-MI-27954 |
MNDR | hsa-miR-20b-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-27955 |
MNDR | hsa-miR-20b-5p | Prostate adenocarcinoma | MNDR-E-MI-27956 |
MNDR | hsa-miR-20b-5p | Kidney cancer | MNDR-E-MI-27957 |
MNDR | hsa-miR-20b-5p | Carcinoma ductal breast | MNDR-E-MI-27958 |
MNDR | hsa-miR-20b-5p | Glioblastoma | MNDR-E-MI-27959 |
MNDR | hsa-miR-20b-5p | Astrocytoma | MNDR-E-MI-27960 |
MNDR | hsa-miR-20b-5p | Glioma | MNDR-E-MI-27961 |
MNDR | hsa-miR-20b-5p | Central nervous system lymphoma | MNDR-E-MI-27962 |
MNDR | hsa-miR-20b-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-27963 |
MNDR | hsa-miR-20b-5p | Osteosarcoma | MNDR-E-MI-27964 |
MNDR | hsa-miR-20b-5p | Liposarcoma | MNDR-E-MI-27965 |
MNDR | hsa-miR-20b-5p | Liver cancer | MNDR-E-MI-27966 |
MNDR | hsa-miR-20b-5p | Cervical adenocarcinoma | MNDR-E-MI-27967 |
MNDR | hsa-miR-20b-5p | Gastric adenocarcinoma | MNDR-E-MI-27968 |
MNDR | hsa-miR-20b-5p | Cervical squamous cell carcinoma | MNDR-E-MI-27969 |
MNDR | hsa-miR-20b-5p | Lung squamous cell carcinoma | MNDR-E-MI-27970 |
MNDR | hsa-miR-20b-5p | Non-small cell lung adenocarcinoma | MNDR-E-MI-27971 |
MNDR | hsa-miR-20b-5p | Lung adenocarcinoma | MNDR-E-MI-27972 |
MNDR | hsa-miR-20b-5p | Adrenocortical cancer | MNDR-E-MI-27973 |
MNDR | hsa-miR-20b-5p | Thyroid carcinoma | MNDR-E-MI-27974 |
MNDR | hsa-miR-20b-5p | Ovarian carcinoma | MNDR-E-MI-27975 |
MNDR | hsa-miR-20b-5p | Myasthenia gravis | MNDR-E-MI-27976 |
MNDR | hsa-miR-20b-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-27977 |
MNDR | hsa-miR-20b-5p | Carcinoma renal cell | MNDR-E-MI-27978 |
MNDR | hsa-miR-20b-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-27979 |
MNDR | hsa-miR-20b-5p | Clear cell renal cell carcinoma | MNDR-E-MI-27980 |
MNDR | hsa-miR-20b-5p | Biliary tract cancer | MNDR-E-MI-27981 |
MNDR | hsa-miR-20b-5p | Cholangiocarcinoma | MNDR-E-MI-27982 |
MNDR | hsa-miR-20b-5p | Esophageal cancer | MNDR-E-MI-27983 |
MNDR | hsa-miR-20b-5p | Lung small cell carcinoma | MNDR-E-MI-27984 |
MNDR | hsa-miR-20b-5p | Synovial sarcoma | MNDR-E-MI-27985 |
MNDR | hsa-miR-20b-5p | Testicular germ cell cancer | MNDR-E-MI-27986 |
MNDR | hsa-miR-20b-5p | T acute lymphoblastic leukemia | MNDR-E-MI-27987 |
MNDR | hsa-miR-20b-5p | Acute t cell leukemia | MNDR-E-MI-27988 |
MNDR | hsa-miR-20b-5p | Heart failure | MNDR-E-MI-27989 |
MNDR | hsa-miR-20b-5p | Breast invasive carcinoma | MNDR-E-MI-27990 |
MNDR | hsa-miR-20b-5p | Hepatocellular carcinoma | MNDR-E-MI-27991 |
MNDR | hsa-miR-20b-5p | B-cell lymphoma | MNDR-E-MI-27992 |
MNDR | hsa-miR-20b-5p | T-cell leukemia | MNDR-E-MI-27993 |
MNDR | hsa-miR-20b-5p | Malignant pleural mesothelioma | MNDR-E-MI-27994 |
MNDR | hsa-miR-20b-5p | Neuroblastoma | MNDR-E-MI-27995 |
MNDR | hsa-miR-20b-5p | Barrett's adenocarcinoma | MNDR-E-MI-27996 |
MNDR | hsa-miR-20b-5p | Hodgkin lymphoma | MNDR-E-MI-27997 |
MNDR | hsa-miR-20b-5p | Colorectal cancer | MNDR-E-MI-27998 |
MNDR | hsa-miR-20b-5p | Nasopharynx carcinoma | MNDR-E-MI-27999 |
MNDR | hsa-miR-20b-5p | Multiple myeloma | MNDR-E-MI-28000 |
MNDR | hsa-miR-20b-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-28001 |
MNDR | hsa-miR-20b-5p | Uterine cervical neoplasms | MNDR-E-MI-28002 |
MNDR | hsa-miR-20b-5p | Ependymoma | MNDR-E-MI-28003 |
MNDR | hsa-miR-20b-5p | Nasopharyngeal cancer | MNDR-E-MI-28004 |
MNDR | hsa-miR-20b-5p | Prostatic neoplasms | MNDR-E-MI-28005 |
MNDR | hsa-miR-20b-5p | Pseudorabies | MNDR-E-MI-28006 |
MNDR | hsa-miR-20b-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-28007 |
MNDR | hsa-miR-20b-5p | Gait ataxia | MNDR-E-MI-28008 |
MNDR | hsa-miR-20b-5p | Stroke lacunar | MNDR-E-MI-28009 |
MNDR | hsa-miR-20b-5p | Barrett's carcinogenesis | MNDR-E-MI-28010 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | AC021078.1 | Homo sapiens | RR00029797 |
TOP